Targeting KRAS mutations in cancer using a novel siRNA delivery technology

使用新型 siRNA 递送技术靶向癌症​​中的 KRAS 突变

• 批准号: nhmrc : 1004146
• 负责人: Dr Carleen Cullinane
• 金额: $ 33.27万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-kras-mutations-delivery-technology/109002
• 关键词: Targeting; KRAS; mutations; cancer; using

Mutations in a gene called KRAS are found in 20% of human cancers but are impossible to target with existing treatments. RNA interference is a promising new way to target genes previously considered undruggable, but there is no way to deliver the molecules required for RNA interference to tumours. We will evaluate the ability of a new nanotechnology based delivery system (antibody targeted minicells) to deliver RNA interference, thereby selectively targeting of KRAS in tumours while avoiding toxicity to normal tissue.

20% 的人类癌症中发现了一种名为 KRAS 的基因突变，但现有的治疗方法无法针对这种突变。 RNA干扰是一种很有前途的新方法，可以靶向以前被认为不可成药的基因，但目前还没有办法将RNA干扰所需的分子传递到肿瘤。我们将评估基于新型纳米技术的递送系统（抗体靶向微细胞）递送 RNA 干扰的能力，从而选择性地靶向肿瘤中的 KRAS，同时避免对正常组织的毒性。